Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.132.00 CHF
Change Today -3.40 / -2.51%
Volume 221.8K
LONN On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Singapore
Frankfurt
SIX Swiss Ex
As of 11:43 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LONN) Snapshot

Open
SFr.135.60
Previous Close
SFr.135.40
Day High
SFr.135.90
Day Low
SFr.132.00
52 Week High
05/5/15 - SFr.136.90
52 Week Low
01/16/15 - SFr.89.13
Market Cap
7.0B
Average Volume 10 Days
158.4K
EPS TTM
SFr.4.56
Shares Outstanding
52.9M
EX-Date
04/10/15
P/E TM
28.9x
Dividend
SFr.2.50
Dividend Yield
1.89%
Current Stock Chart for LONZA GROUP AG-REG (LONN)

Related News

No related news articles were found.

lonza group ag-reg (LONN) Related Businessweek News

View More BusinessWeek News

lonza group ag-reg (LONN) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Specialty Ingredients and Pharma&Biotech. The Specialty Ingredients segment offers consumer care products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B compounds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields and food quality; industrial Solutions, including preservatives and biocide blends; products and services that enhance the quality of wood; and sanitizers and other treatment chemicals for pools, spas, water parks, as well as in the treatment of surface waters for drinking, agriculture, irrigation, food processing, and industrial applications. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, peptide syntheses, antibody drug conjugates, cytotoxic, and small organic molecules. It also offers cell culture, transfection, and molecular biology tools for life-science research; media used in the production of therapeutics; endotoxin detection assays; and products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. Lonza Group Ltd. was founded in 1897 and is headquartered in Basel, Switzerland.

9,809 Employees
Last Reported Date: 02/26/15
Founded in 1897

lonza group ag-reg (LONN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.3M
Compensation as of Fiscal Year 2014.

lonza group ag-reg (LONN) Key Developments

Nikon Corporation Signs a Strategic Collaboration Agreement with Lonza to Establish a New Company

Nikon Corporation announced that it signed a strategic collaboration agreement with Lonza to establish a new company, wholly-owned by Nikon, dedicated to regenerative medicine contract manufacturing. The agreement includes access to Lonza's quality and operating systems, facility design and on-going consulting services for the establishment of the contract manufacturing facility in Japan. Nikon has formed a strategic collaboration with Lonza, which has an excellent track record in the global development and manufacture of cell products for regenerative medicine, and will enter into the contract manufacturing business. Purpose for entering the regenerative medicine Contract Manufacturing business By entering into cell product contract manufacturing business, Nikon will acquire the know-how to manufacture cells, including somatic stem cells, and will accelerate its effort to realize future practical applications of iPSCs in the field of regenerative medicine. Nikon will actively be engaged for solution of these issues by introducing the high-quality cell manufacturing technology and technical know-how from Lonza, together with Nikon's core technology, optics technology and image analysis technology for successful cell contract manufacturing activity. By entering into a new regenerative medicine contract manufacturing business, Nikon will actively be contributing to the early realization of Japan's regenerative medicine, and will expand its business domain into adjacent technology areas.

Lonza Group Ltd, Q1 2015 Earnings Call, Apr 28, 2015

Lonza Group Ltd, Q1 2015 Earnings Call, Apr 28, 2015

Lonza Group Ltd to Report Q1, 2015 Results on Apr 28, 2015

Lonza Group Ltd announced that they will report Q1, 2015 results on Apr 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LONN:VX SFr.132.00 CHF -3.40

LONN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $127.40 USD -0.27
Clariant AG SFr.20.12 CHF -0.10
Croda International PLC 2,925 GBp -52.00
PerkinElmer Inc $52.73 USD -0.36
Wacker Chemie AG €98.91 EUR -3.11
View Industry Companies
 

Industry Analysis

LONN

Industry Average

Valuation LONN Industry Range
Price/Earnings 31.4x
Price/Sales 2.0x
Price/Book 3.5x
Price/Cash Flow 31.9x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.